1 April 2020 price disclosure confirmed prices

31 March 2020 - Confirmed 1 April 2020 prices resulting from the 2020 April cycle of price disclosure have been published ...

Read more →

Updated Financial Estimates workbook and manual

30 March 2020 - An updated version of the Utilisation and Cost Model workbook and a user manual are now available ...

Read more →

Public Summary Documents - November 2019 PBAC meeting (supplement)

26 March 2020 - Additional insights from the second round of public summary documents (first time rejections and deferrals). ...

Read more →

Public Summary Documents - November 2019 PBAC meeting

25 March 2020 - Insights from the second round of public summary documents (first time rejections and deferrals). ...

Read more →

EMA publishes agenda for 23-26 March CHMP meeting

23 March 2020 - The EMA has published a draft agenda for this week's CHMP meeting. ...

Read more →

NICE publishes first rapid COVID-19 guidelines

21 March 2020 - New guidelines cover the management of patients in critical care, the management of patients who are having ...

Read more →

PBAC Public Summary Documents - November 2019 meeting (first time rejections and deferrals)

20 March 2020 - The public summary documents (first rejections and deferrals) from the November 2019 PBAC meeting are now available. ...

Read more →

Decision to decline inactive medicines funding applications

20 March 2020 - To give people more clarity about what medicines PHARMAC is, or is not, actively considering for ...

Read more →

ICER releases draft evidence report on obeticholic acid for non-alcoholic steatohepatitis

19 March 2020 - Public comment period on preliminary draft now open until 24 June 2020; requests to make oral comment ...

Read more →

Coronavirus (COVID-19) update: FDA issues guidance for conducting clinical trials

18 March 2020 - The U.S. Food and Drug Administration today issued a guidance for industry, investigators and institutional review ...

Read more →

Drug Utilisation Sub-Committee outcome statement

18 March 2020 - The outcome statement from the February 2020 Drug Utilisation Sub-Committee meeting is now available. ...

Read more →

ICER releases evidence report on treatments for sickle cell disease

12 March 2020 - Three new treatments use different mechanisms to improve patient outcomes, offering important options for patients. ...

Read more →

Reformatting Product Information: frequently asked questions

6 March 2020 - A new product information form was approved on 8 November 2017, with a commencement date of ...

Read more →

Standardised redactions to Public Summary Documents – nominations open for participation in the final trial, and implementation from July 2020

5 March 2020 - The Department is now seeking nominations from sponsors with submissions due to be considered at the ...

Read more →

ICER issues final report and policy recommendations on acute treatments for migraine

25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans. ...

Read more →